Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ingenuity Systems, a provider of information solutions for life science researchers, has signed a multi-year agreement with AstraZeneca, a pharmaceutical company, which plans to expand the utilization of Ingenuity Pathways Analysis in its research and target discovery programs to gain domain knowledge of disease-related pathways and targets.
Subscribe to our email newsletter
As part of the agreement, AstraZeneca researchers plan to leverage the analysis application, to build biological models, analyze data, and answer biological and chemical questions in their effort to identify and progress promising targets, said Ingenuity Systems.
Ian Dix, principal informatics scientist of AstraZeneca, said: “Ingenuity Pathways Analysis (IPA) is an extensive platform for understanding and communicating the dynamic behaviors of complex biological systems. IPA can support a wide range of research objectives across our target and biomarker discovery programs, such as providing insight into target efficacy, drugability and, increasingly, toxicity.”
Sean Scott, senior vice president of sales and operations at Ingenuity Systems, said: “We are pleased to enhance and extend our relationship with AstraZeneca and to continue to provide AstraZeneca’s researchers with greater workflow and decision support. IPA continues to deliver value to AstraZeneca researchers by providing the right capabilities and content to understand biological systems and uncover insights that impact business decisions.”